BATS · WDNA
Financial Services · Asset Management
$24.67
Down-$0.06 (-0.23%)
Updated Oct 30, 2026, 11:46 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · WDNA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
WDNA closed at $24.67 after 21 trading sessions, up 4.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $25.0299 | $25.0299 | $24.55 | $24.6709 | 1.99K |
| Oct 28, 2026 | $24.04 | $24.6057 | $24.04 | $24.6057 | 806.37 |
| Oct 27, 2026 | $23.211 | $23.9635 | $23.211 | $23.9635 | 2.62K |
| Oct 26, 2026 | $23.155 | $23.33 | $23.155 | $23.1754 | 2.48K |
| Oct 23, 2026 | $23.0448 | $23.0448 | $23.0448 | $23.0448 | 121.09 |
| Oct 22, 2026 | $23.40 | $23.40 | $23.05 | $23.1755 | 1.47K |
| Oct 21, 2026 | $23.73 | $23.73 | $23.5151 | $23.5151 | 1.19K |
| Oct 20, 2026 | $22.93 | $23.48 | $22.86 | $23.3725 | 5.33K |
| Oct 19, 2026 | $22.50 | $22.7996 | $22.49 | $22.6861 | 2.81K |
| Oct 16, 2026 | $23.15 | $23.29 | $22.295 | $22.3048 | 2.44K |
| Oct 15, 2026 | $23.285 | $23.285 | $23.2139 | $23.2139 | 659.29 |
| Oct 14, 2026 | $22.78 | $22.81 | $22.70 | $22.8004 | 1.55K |
| Oct 13, 2026 | $22.81 | $22.81 | $22.6201 | $22.67 | 1.25K |
| Oct 12, 2026 | $23.34 | $23.34 | $22.945 | $23.0148 | 3.12K |
| Oct 9, 2026 | $23.49 | $23.6199 | $23.44 | $23.50 | 1.68K |
| Oct 8, 2026 | $22.58 | $22.6001 | $22.58 | $22.6001 | 1.77K |
| Oct 7, 2026 | $22.76 | $23.00 | $22.55 | $22.7852 | 2K |
| Oct 6, 2026 | $24.69 | $24.74 | $22.9328 | $22.9328 | 2.64K |
| Oct 5, 2026 | $23.779 | $24.306 | $23.779 | $24.306 | 1.09K |
| Oct 2, 2026 | $23.71 | $23.71 | $23.48 | $23.68 | 2.46K |
| Oct 1, 2026 | $23.935 | $23.97 | $23.6324 | $23.6324 | 2.09K |
The latest Smart Investors Daily articles mentioning WDNA.
Company
Market Activity
Research & News
WDNA research
Company profile and research snapshot.
The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
Consensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Sep 26, 2026
David Rubenstein, co-founder and co-chairman of The Carlyle Group, discusses his move from private equity into sports investing. Read more here...
SeekingAlpha · Aug 7, 2026
Health Care ended a five-day losing streak on Wednesday with a 1.34% rally. The streak tied the five days ending June 18 for the sectorâs longest of 2026.
SeekingAlpha · Jul 17, 2026
SpaceXâs watershed IPO highlighted how rapidly space has evolved from a niche market into a strategically important sector. Read more here.
SeekingAlpha · Jul 10, 2026
Equity investors should cast a wide net to capture the healthcare sectorâs full potential. Read more here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WDNA.
No results
No recent SID articles mention WDNA.
